Swiss pharmaceutical giant Novartis is stepping up its China presence with a planned investment exceeding 3.3 billion yuan ($460 million), signaling the country’s central role in its long-term global strategy. The announcement came during the 2026 China Development Forum in Beijing, marking the company’s eighth consecutive attendance.
“China is critical to Novartis’ long-term development and innovation,” said CEO Vas Narasimhan. “We aim to be a trusted healthcare partner and bring transformative medicines to Chinese patients.”
Strategic Expansion Across R&D and Manufacturing
Novartis plans a multi-pronged investment approach this year:
- Changping Plant (Beijing): The facility, operational since 1987, will undergo a 1.5 billion yuan upgrade, adding advanced sterile preparation, liquid filling, and packaging capabilities.
- Shanghai Campus: Marking its 10th anniversary, the campus will expand with a 1.8 billion yuan investment alongside partners, reinforcing its role as Novartis’ China headquarters.
- Radioligand Therapy Facility (Haiyan, Zhejiang): The first of its kind in China, this 600 million yuan site positions Novartis to meet growing domestic demand for innovative cancer therapies.
The expansions underline China’s evolution from a high-growth consumer market to a global innovation hub within Novartis’ corporate architecture.
China: A Growing Hub for Global Pharma Innovation
Novartis’ move reflects broader trends among multinational pharmaceutical companies:
- Eli Lilly announced a $3 billion, 10-year investment plan in China to localize production of oral solid drugs and next-generation GLP-1 therapies.
- AstraZeneca plans to invest over 100 billion yuan by 2030 to expand drug manufacturing and R&D footprint.
Executives note that China now accounts for around 30% of global novel drug development, second only to the U.S. In 2025, China approved 76 innovative drugs, up from 48 in 2024, underscoring the accelerating pace of innovation and regulatory efficiency.
Policy Tailwinds and Emerging Opportunities
Commerce Minister Wang Wentao highlighted that foreign firms have deepened their presence over the years, turning China into a strategic R&D hub. The 15th Five-Year Plan (2026-30) reinforces a health-first strategy, positioning biopharmaceuticals as an emerging pillar industry and pledging stronger IP protection, greater policy transparency, and faster regulatory approvals.
These measures create fertile ground for multinational firms to capture new opportunities in Healthy China 2030, while scaling production and accelerating delivery of innovative therapies to patients.
Implications for Global Biopharma
Novartis’ China strategy exemplifies a shift in multinational pharma operations: integrating local production, R&D, and innovation into global pipelines. By leveraging China’s regulatory reforms, skilled workforce, and expanding patient base, companies can accelerate global drug development while anchoring their presence in one of the world’s largest healthcare markets.
For investors and industry watchers, the message is clear: China is no longer just a market—it is a strategic engine for global pharmaceutical innovation, with multinationals increasingly treating their China operations as critical to long-term competitiveness.